| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2011.36.1709 |
| P698 | PubMed publication ID | 22370318 |
| P2093 | author name string | Vera Hirsh | |
| Shukui Qin | |||
| Jin Soo Lee | |||
| Christian Manegold | |||
| Keunchil Park | |||
| Reury-Perng Perng | |||
| Yuh-Min Chen | |||
| Peter Langmuir | |||
| Laura Emerson | |||
| Cesar R Blajman | |||
| P433 | issue | 10 | |
| P921 | main subject | lung cancer | Q47912 |
| phase III clinical trial | Q42824827 | ||
| placebo | Q269829 | ||
| vandetanib | Q7914515 | ||
| P304 | page(s) | 1114-1121 | |
| P577 | publication date | 2012-02-27 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR) | |
| P478 | volume | 30 |
| Q53001245 | A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer. |
| Q30300114 | A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients |
| Q58088398 | A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors |
| Q54364572 | A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. |
| Q33408559 | A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). |
| Q92367546 | A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report |
| Q35545693 | A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies |
| Q36068707 | A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients |
| Q35206630 | Activated RET and ROS: two new driver mutations in lung adenocarcinoma |
| Q49188770 | Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review |
| Q42359608 | Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis |
| Q38077494 | An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents |
| Q47095393 | Angiogenesis Inhibitors in NSCLC. |
| Q26775394 | Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). |
| Q38130312 | Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales |
| Q38669276 | Anti-angiogenesis in Personalized Therapy of Lung Cancer |
| Q39309830 | Anti-angiogenic therapy in advanced non-small cell lung carcinoma (NSCLC): is there a role in subsequent lines of therapy? |
| Q38829551 | Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine |
| Q38000486 | Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? |
| Q55168137 | Antiangiogenic therapies in non-small-cell lung cancer. |
| Q28085104 | Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer? |
| Q37003332 | Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma |
| Q57456582 | Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials |
| Q37428434 | Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial |
| Q38077126 | Clinical meta-analyses of targeted therapies in adenocarcinoma |
| Q38956300 | Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence |
| Q37099594 | Combining molecular targeted agents with radiation therapy for malignant gliomas |
| Q37701719 | Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials |
| Q41474415 | Comprehensive Cytomorphologic Analysis of Pulmonary Adenoid Cystic Carcinoma: Comparison to Small Cell Carcinoma and Non-pulmonary Adenoid Cystic Carcinoma |
| Q38166329 | Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. |
| Q36996220 | Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC) |
| Q50607902 | Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. |
| Q95322818 | Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer |
| Q33938441 | Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer |
| Q33418555 | Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. |
| Q37269316 | Emerging options for the management of non-small cell lung cancer |
| Q36660669 | Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease |
| Q38168795 | Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies |
| Q38667071 | Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis |
| Q34669260 | Fool's gold, lost treasures, and the randomized clinical trial |
| Q28533949 | From bench to bedside: lessons learned in translating preclinical studies in cancer drug development |
| Q37392650 | Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma |
| Q28079328 | Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients |
| Q36729895 | Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials |
| Q49244147 | Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review. |
| Q36024704 | Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis |
| Q34144848 | Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage |
| Q41263498 | Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib |
| Q37347532 | Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy |
| Q36859958 | Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma |
| Q35346839 | Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses |
| Q27853306 | NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer |
| Q35660763 | New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond |
| Q35667806 | New molecular targeted therapies for advanced non-small-cell lung cancer. |
| Q27003440 | Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design |
| Q27693185 | Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors |
| Q36890658 | Novel compounds in the treatment of lung cancer: current and developing therapeutic agents |
| Q38110796 | Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. |
| Q37038500 | Novel targets in non-small cell lung cancer: ROS1 and RET fusions |
| Q33633424 | Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients |
| Q36738554 | Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer |
| Q35553791 | Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma |
| Q39665887 | Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy |
| Q35177011 | Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer |
| Q34272887 | Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis |
| Q35677270 | QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. |
| Q37007890 | Radiation therapy for early stage lung cancer |
| Q35113397 | Review of the treatment of metastatic non small cell lung carcinoma: A practical approach |
| Q38678038 | Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials |
| Q36301449 | Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab |
| Q47128966 | Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials |
| Q37042424 | Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review |
| Q38936376 | Second-Line Treatment of Non-Small Cell Lung Cancer: New Developments for Tumours Not Harbouring Targetable Oncogenic Driver Mutations |
| Q36904574 | Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers |
| Q35116206 | Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors |
| Q41593429 | Strategies targeting angiogenesis in advanced non-small cell lung cancer |
| Q30356434 | Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update |
| Q34898454 | Target therapies in lung cancer |
| Q90427383 | Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions |
| Q27022852 | Targeted therapies in development for non-small cell lung cancer |
| Q38390200 | Targeted therapy for non-small cell lung cancer: current standards and the promise of the future |
| Q37709922 | Targeted therapy for non-small-cell lung cancer: past, present and future |
| Q37246286 | Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer |
| Q47601932 | Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes |
| Q37847070 | Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor |
| Q38154236 | Targeting angiogenesis in advanced non-small cell lung cancer |
| Q38389997 | Targeting angiogenesis in lung cancer - Pitfalls in drug development |
| Q46358843 | The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer |
| Q38292875 | The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer |
| Q38462638 | The role of anti-angiogenesis in non-small-cell lung cancer: an update |
| Q38258948 | Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors |
| Q24564024 | Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future |
| Q35908430 | Tyrosine kinase inhibitors in lung cancer |
| Q35667802 | Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? |
| Q34160907 | Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion |
| Q38020834 | Vandetanib for the treatment of metastatic medullary thyroid cancer |
| Q41167117 | Vandetanib in advanced non small cell lung cancer: a promise unfulfilled |
| Q39203869 | Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial |
| Q39218984 | Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency |
| Q35200470 | ZEPHYR: failure of a "spring wind" in lung cancer |
| Q54397002 | [Significances of RET fusion gene in non-small cell lung cancer]. |
Search more.